TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00748423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: NO in inhalation for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in inhalation for 3 days
Study: NCT01047982

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol
Description: myo-inositol 2 grams plus folic acid 400 mcg twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: folic acid 400 mcg
Description: 2 pills a day
Study: NCT03160820

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, mumps and rubella Combined Vaccine, Live
Description: Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
Study: NCT03242811

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan of knee, ankle and wrist
Description: At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence.
Study: NCT03160820

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, mumps and rubella Combined Vaccine, Live
Description: Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, mumps and rubella Combined Vaccine, Live
Description: Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, mumps and rubella Combined Vaccine, Live
Description: Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
Study: NCT02806453

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: thickened formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: thickened formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mg alginate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mg alginate
Study: NCT02311660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation Device
Description: Cyberonics VNS System
Study: NCT02806453

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reassurance with lifestyle changes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reassurance with lifestyle changes
Study: NCT01301833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glinide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biguanide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-glucosidase inhibitor
Study: NCT01813448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: oral
Study: NCT02688881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Rapamune
Study: NCT03540628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thiamine and Vitamin C
Description: Supplementary vitamins for the patient in septic shock
Study: NCT02496715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg / salmeterol 50 mcg
Description: Brand inhaler containing pMDI containing fluticasone and salmeterol
Study: NCT01813448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02373774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
Study: NCT04270539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Participants will be given 20-min nap opportunity in the classroom on a daily basis during school-days.
Study: NCT00278746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc and ORS
Description: Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities

Intervention type: DRUG
Group type: OTHER
Intervention: ORS only
Description: Promoted routine management of diarrhea in underfive with ORS
Study: NCT02087969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Study: NCT02197390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family wellness workshops
Description: Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family wellness workshops
Description: Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity chronic care model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity chronic care model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity, healthy eating, water drinking, healthy sleep promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity, healthy eating, water drinking, healthy sleep promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity, healthy eating, water drinking, healthy sleep promotion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment, policy, systems changes in clinic setting only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment, policy, systems changes in clinic setting only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment, policy, systems changes in clinic setting only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment, policy, and systems changes in schools, early child care education & recreation
Study: NCT04448899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine Oral Tablet
Description: Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blacebo plus standard treatment
Description: Blacebo plus standard treatment
Study: NCT02087969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Study: NCT01588600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber
Description: Fiber added to breakfast
Study: NCT03662438

Intervention type: OTHER
Group type: OTHER
Intervention: Home-based physiotherapy program
Description: The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
Study: NCT02496715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic fluticasone propionate 100 mcg / salmeterol 50 mcg
Description: Generic inhaler containing pMDI containing fluticasone and salmeterol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler
Study: NCT01266967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Study: NCT04346017

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytokines dosage
Description: Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytokines dosage
Description: Dosage of inflammatory cytokines and other markers of systemic inflammatory syndromes (TNFa, IFNg, IL1, IL7, IL10, IL12, IL17, sCD25, sCD163, sCD14, IL-6, IL6-R, complex IL6-IL6R, glycolsylated ferritin...).

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complement dosage
Description: Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Complement dosage
Description: Dosage of the complement parameters: CH50, C3, C4, C3d, C5a, SC5b-9, C4a, MASP-2.
Study: NCT02011646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Description: The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Controlled Intervention
Description: The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
Study: NCT01588600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Fiber added to breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Fiber
Description: Fiber added to breakfast
Study: NCT01063647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 10 g/m² i.v. infusion, day -6, -5, -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 12 g/m² i.v. infusion, day -6, -5, -4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14 g/m² i.v. infusion, day -6, -5, -4
Study: NCT00554047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Memory Clinic
Description: Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Practitioners
Description: Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
Study: NCT05675501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated Benzoyl Peroxide Cream
Description: Subjects will use a pea-size amount for each area of the face

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Encapsulated Benzoyl Peroxide Cream
Description: Subjects will use a pea-size amount for each area of the face
Study: NCT04124640

Intervention type: OTHER
Intervention: Patients' data (baseline characteristics, clinical and outcomes) from routine care visits
Description: Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
Study: NCT00857857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: Positive control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study: NCT03125551

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: Ginger dosage at daily recommended allowance

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic
Description: Garlic dosage at daily recommended allowance

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Biloba
Description: Ginkgo Biloba dosage at daily recommended allowance

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: Ginseng dosage at daily recommended allowance

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosage strategy
Study: NCT04266054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Storytelling Intervention
Description: 12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
Study: NCT01925547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar curcumin
Description: 80 mg micellar curcumin (oral) three times a day for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
Study: NCT04489472

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beet-it Juice
Description: Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beet-it Juice
Description: Patients will ingest 1 bottle (70ml) of beet-it juice (98% concentrated beet juice, 2% lemon juice containing 400 mg/6.5 mmol nitrate).
Study: NCT01932333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813 50 mg
Description: Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
Study: NCT04436172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: The spinal anesthesia was given by a trained anesthetist in an equipped room, after all aseptic measures. A 20 gauge intravenous cannula was inserted for maintaining a peripheral line and 0.9% normal saline was used for loading the patient. The pulse and blood pressure were monitored non-invasively. The median approach was utilized and intrathecal space was accessed via 25 gauge Quiincke bevel(Becton Dickinson/Pakistan ) through L4-L5. A block was performed by using 5 mg hyperbaric bupivacaine (Abocain 0.5%/Abbot) after ensuring swirling. Block height was monitored via pinprick test after every three minutes, for 20 minutes until there was no progression. The couple was left alone. The couples received prior training and were explained precautions.
Study: NCT01356446

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implementation surgical checklist
Description: a checklist according to the suggestions raised by the WHO is implemented
Study: NCT01646606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent oxygen monitoring
Description: Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous oxygen monitoring
Description: Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
Study: NCT03521141

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: FDA-approved smoking cessation pharmacotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study: NCT04203082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention
Description: Single session intervention of psychoeducation + exposure treatment to the operating room and procedural steps of a cesarean delivery
Study: NCT03662438

Intervention type: DEVICE
Group type: OTHER
Intervention: Prescription of a Portable Oxygen Concentrator (POC) device
Description: Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device \[Philips SimplyGo Mini\] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
Study: NCT03521141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: FDA-approved smoking cessation pharmacotherapy
Study: NCT04203082

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard of care for education about the cesarean /delivery planning varies across the two hospitals. At Children's Hospital Colorado, anesthesiologists are included in the delivery planning meetings where the patients have the opportunity to review anesthetic technique and ask questions.
Study: NCT04185233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Games on an iPad
Description: Many games will be programmed on the iPad and organized by age. The child will choose one game and play it during all the procedure time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Nitrous oxide will be provided to the child by a mask 3 minutes before the intervention and during all this one.
Study: NCT01611142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761 (mogamulizumab)
Description: 1 mg/kg administered intravenously weekly x 4 then every other week until progression
Study: NCT01144858

Intervention type: OTHER
Intervention: a complete transesophageal echocardiography
Description: All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
Study: NCT01348074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose
Description: For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
Study: NCT03538496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Single shot 20 ml 0.25 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Single shot 20 ml 0.25 bupivacaine
Study: NCT01932333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813 100 mg
Description: Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).